ReviewFrontiers in oncology2025
Norrin in cancer: from a promising prognostic biomarker to a novel therapeutic target.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer continues to pose significant risks to public health globally due to incomplete therapeutic conquests even though significant advances have been achieved in the field of oncology. Therefore, understanding the molecular mechanisms driving tumorigenesis and progression is critical for developing novel treatment strategies to achieve effective cancer treatment. Norrin, the secreted cystine-knot protein originally recognized for its functional role in retinal vascular development an neuronal protection, is now implicated in oncogenic processes. This review synthesizes the existing evidence on Norrin's involvement in tumors, highlighting its aberrant expression across multiple malignancies and its functional role in cancer cell proliferation, migration, invasion, and tumor-associated angiogenesis. The compelling data reported in this review suggest that dysregulated Norrin signaling promotes oncogenesis in various cancer types. Furthermore, the mechanistic basis of Norrin's tumorigenic effect is discussed, and the therapeutic potential of targeting Norrin is evaluated to provide novel insights for future diagnostic and therapeutic development in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.